VYNE Therapeutics Profit Margin

The latest profit margin for VYNE is -4417.28% as of June 2026. That compares with -8097.69% in the prior-year period — up 45.5% year over year. That is below the Healthcare sector average of 21.34%. Investors often review this figure alongside VYNE Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, VYNE's profit margin moved from -8097.69% to -4417.28% — a 45.5% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in VYNE Therapeutics's valuation or profitability profile.

Against Healthcare companies, VYNE currently prints -4417.28% for profit margin, while the sector average sits near 21.34%. That is roughly 20804.2% below the sector mean. Large gaps often invite a closer look at VYNE Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively VYNE Therapeutics converts resources into returns. At -4417.28%, VYNE may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -8097.69% in the prior-year period — up 45.5% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting VYNE's profit margin (-4417.28%), review year-over-year change from -8097.69%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.